BMS Reports Data from P-IIIb/IV (PSORIATYK SCALP) and Real-World (RePhlect) Studies of Sotyktu for Moderate-to-Severe Scalp Psoriasis
Shots:
- The 52wks. P-IIIb/IV (PSORIATYK SCALP) study assessed Sotyktu vs PBO to treat mod. to sev. scalp psoriasis, with wk.16 efficacy & safety analysis involving 154 subjects
- Study showed ss-PGA 0/1 response in 48.5% vs 13.7% & 51% vs 4.3% (patients with sPGA ≥3), PSSI 90 in 38.8% vs 2% and mean CFB in scalp-specific itch among -3.2 vs -0.7. Improvements in scalp itch (41.7% vs 9.8%), pain (26.2% vs 11.8%), flaking (53.4% vs 19.6%) & whole-body itch (39.8% vs 13.7%) were also seen at wk.16
- Real-world RePhlect study in 118 patients showed efficacy similar to POETYK PSO trials post 6mos. PASI scores ≤3 was seen in 67.9%, BSA ≤3% in 64.1% & IGA scores of 0/1 in 46.8% among overall population, with similar results in mod. to sev. plaque PsO patients
Ref: BMS | Image: BMS
Related News:- BMS Reports Results from the P-III (POETYK PSO) Long-Term Extension Study of Sotyktu for Treating Plaque Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
